This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, R. Articles by Rabkin, S. D. Search for Related Content PubMed PubMed Citation Articles by Liu, R. Articles by Rabkin, S. D.

Oncolytic Herpes Simplex Virus Vector Therapy of Breast Cancer in C3(1)/SV40 T-antigen Transgenic Mice

Molecular Neurosurgery Laboratory, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts

Requests for reprints: Samuel Rabkin, Molecular Neurosurgery Laboratory, Massachusetts General Hospital East, 13th Street, Building 149, Box 17, Charlestown, MA 02129; E-mail: Rabkin{at}helix.mgh.harvard.edu.

Oncolytic herpes simplex virus vectors are a promising strategy for cancer therapy, as direct cytotoxic agents, inducers of antitumor immune responses, and as expressers of anticancer genes. Progress is dependent upon representative preclinical models to evaluate therapy. In this study, two families of oncolytic herpes simplex virus vectors (G207 and NV1020 series) that have been in clinical trials were examined for the treatment of breast cancer, using the C3(1)/T-Ag transgenic mouse model. Female mice spontaneously develop mammary carcinomas, and the C3(1)/T-Ag–derived tumor cell line M6c forms implantable tumors. Both in vitro and in vivo, G47, derived from G207 by deletion of ICP47 and the US11 promoter, was more efficacious than G207. Whereas NV1023, derived from NV1020 by deletion of ICP47 and insertion of LacZ, was as cytotoxic to M6c cells in vitro as G47, it did not inhibit the growth of s.c. M6c tumors but did extend the survival of intracerebral tumor bearing mice. In contrast, NV1042, NV1023 expressing interleukin 12, inhibited s.c. M6c tumor growth to a similar extent as G47, but was less effective than NV1023 in intracerebral tumors. In the spontaneously arising mammary tumor model, when only the first arising tumor per mouse was treated, G47 inhibited the growth of a subset of tumors, and when all tumors were treated, G47 significantly delayed tumor progression. When the first mammary tumor was treated and the remaining mammary glands removed, NV1042 was more efficacious than G47 at inhibiting the growth and progression of injected tumors.

Key Words: virotherapy • herpes simplex virus • transgenic mouse • mammary adenocarcinoma • brain metastases

This article has been cited by other articles:

				L. Menotti, G. Nicoletti, V. Gatta, S. Croci, L. Landuzzi, C. De Giovanni, P. Nanni, P.-L. Lollini, and G. Campadelli-Fiume Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells PNAS, June 2, 2009; 106(22): 9039 - 9044. [Abstract] [Full Text] [PDF]

				S. Varghese, S. D. Rabkin, G. P. Nielsen, U. MacGarvey, R. Liu, and R. L. Martuza Systemic Therapy of Spontaneous Prostate Cancer in Transgenic Mice with Oncolytic Herpes Simplex Viruses Cancer Res., October 1, 2007; 67(19): 9371 - 9379. [Abstract] [Full Text] [PDF]

				X. Lun, D. L. Senger, T. Alain, A. Oprea, K. Parato, D. Stojdl, B. Lichty, A. Power, R. N. Johnston, M. Hamilton, et al. Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV{Delta}M51) on Multifocal and Invasive Gliomas. J Natl Cancer Inst, November 1, 2006; 98(21): 1546 - 1557. [Abstract] [Full Text] [PDF]

				D. Cross and J. K. Burmester Gene therapy for cancer treatment: past, present and future. Clin. Med. Res., September 1, 2006; 4(3): 218 - 227. [Abstract] [Full Text] [PDF]